Vorstellung der Themen des 13. IMI2 Calls

Datum:    Donnerstag der 30.11.2017
Zeit:       10:00 - 11:30 Uhr

Bitte beachten Sie: Die Sprache wird via Voice over IP oder per Telefon übertragen, Sie benötigen daher lediglich Lautsprecher um zuhören zu können.

Agenda

10:00Begrüßung

N.N. (VBU)

Thorsten Ruppert (vfa und vfa bio)

Jan Skriwanek (NKS Gesundheit in der NKS Lebenswissenschaften, NKS-G)

10:10 

Der IMI2-Call-Prozess / Unterstützung durch BMBF/NKS-G 
Jan Skriwanek, NKS-G

10:15 

Vorstellung der Themen des 13. IMI2-Calls
(inklusive Fragen und Antworten nach jedem Topic)

1. Assessment of the uniqueness of diabetic cardiomyopathy relative to
        other forms of heart failure using unbiased pheno-mapping approaches

        Matthias Gossel (Sanofi)

2. Genome-environment interactions in inflammatory skin disease

        Peter Hecht (Sanofi)

3. The value of diagnostics to combat antimicrobial resistance by
        optimising antibiotic use

        N.N. (Organisation xyz)

4. Mitochondrial dysfunction in neurodegeneration

        N.N. (Organisation xyz)

5. Support and coordination action for the projects of the
        neurodegeneration area of the innovative medicines initiative

        Mariana Constantinovici (Janssen)

 

6. A sustainable European induced pluripotent stem cell platform

        Mariana Constantinovici (Janssen)

7. Linking digital assessment of mobility to clinical endpoints to drive
        regulatory acceptance and clinical practice

        Roubenoff, Ronenn (Novartis)

8. Human tumour microenvironment immunoprofiling

        Ralph Lindemann (Merck KGaA)

9. CONCEPTION – continuum of evidence from pregnancy exposures,
        reproductive toxicology and breastfeeding to improve outcomes now

        Stephan Korte (Novartis)

10. Improving the preclinical prediction of adverse effects of
        pharmaceuticals on the nervous system

        Philippe Bordes (Sanofi)

11. Translational safety biomarker pipeline (TRANSBIOLINE): enabling
        development and implementation of novel safety biomarkers
        in clinical trials and diagnosis of disease

        N.N. (Organisation xyz)

12. Federated and privacy-preserving machine learning in support of drug
        discovery

        Mariana Constantinovici (Janssen)

13. Pilot programme on a clinical compound bank for repurposing
        (Cardiovascular diseases and diabetes, Respiratory diseases,
        Neurodegenerative diseases, Rare/orphan diseases)

        N.N. (Organisation xyz)

11:30Ende des Webinars

Anmeldung zum Webinar

IMI Anmeldung

Kontakt

Kontakt:

Frau Dr. Sydow

vfa bio 030/20604-310

s.sydow(at)vfa.de    

   

   

Herr Dr. Scriba

VBU 069/7564-124

scriba(at)dechema.de    

   

Herr Skriwanek

NKS-G 0228/3821-1677

Jan.Skriwanek(at)dlr.de

 

VBU Info

Veranstalter

Technischer Support

cme24 Ltd.
Zeppelinstr. 2
76185 Karlsruhe
Tel: +49 (0)721 9595 611
E-Mail: support@cme24.de

© 2007-2017 cme24 ltd.